Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iscalimab in Graves' Disease
NCT02713256Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2016
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of iscalimab in Graves' disease, sponsored by Novartis. Primary endpoints: Percentage of Participants Whose Thyroid Stimulating Hormone (TSH) Levels Normalize After 12 Week Treatment, Percentage of Participants Whose Total Triiodothyronine (Total T3) Levels Decrease After 12 Week Treatment and 1 more. Started Apr 2016; status: completed.
02
Drugs
iscalimab
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT02713256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02713256.